NASDAQ:TROV - Cardiff Oncology Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$9.15
▼ -0.57 (-5.86%)
Get New Cardiff Oncology Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TROV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TROV

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Cardiff Oncology in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $9.15.
N/A
The current consensus among 0 polled investment analysts is to n/a stock in Cardiff Oncology. This rating has held steady since January 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/15/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/14/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/13/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/11/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/9/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/8/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/6/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/8/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/28/2020Noble FinancialReiterated RatingOutperformMedium
i
10/3/2019Maxim GroupReiterated RatingBuy$6.00Low
i
Rating by Jason McCarthy at Maxim Group
10/2/2019Noble FinancialReiterated RatingBuy$23.00Low
i
Rating by Ahu Demir at Noble Financial
8/28/2019Noble FinancialReiterated RatingBuy$23.00Low
i
Rating by Ahu Demir at Noble Financial
8/9/2019Maxim GroupReiterated RatingBuy$6.00Medium
i
Rating by Jason McCarthy at Maxim Group
7/31/2019Maxim GroupSet Price TargetBuy$6.00N/A
i
Rating by Jason McCarthy at Maxim Group
5/24/2019Noble FinancialSet Price TargetBuy$23.00Low
i
Rating by Ahu Demir at Noble Financial
5/23/2019Maxim GroupSet Price TargetBuy$8.00Low
i
Rating by Jason McCarthy at Maxim Group
5/10/2019Noble FinancialSet Price TargetBuy$5.00Medium
i
Rating by Ahu Demir at Noble Financial
5/8/2019Maxim GroupSet Price TargetBuy$8.00Medium
i
Rating by Jason McCarthy at Maxim Group
4/2/2019Maxim GroupSet Price TargetBuy$8.00Low
i
Rating by Jason McCarthy at Maxim Group
3/8/2019Noble FinancialSet Price TargetOutperform$27.00 ➝ $20.00High
i
Rating by Ahu Demir at Noble Financial
3/7/2019Maxim GroupReiterated RatingBuy$8.00High
i
Rating by Jason McCarthy at Maxim Group
3/1/2019Maxim GroupBoost Price TargetPositive ➝ Buy$8.00 ➝ $18.00High
i
Rating by Jason McCarthy at Maxim Group
2/21/2019Noble FinancialReiterated RatingBuyMedium
i
Rating by Ahu Demir at Noble Financial
2/1/2019Noble FinancialReiterated RatingBuyLow
i
1/7/2019Noble FinancialInitiated CoverageOutperform$31.20High
i
8/6/2018Maxim GroupReiterated RatingBuyLow
i
Rating by Jason McCarthy at Maxim Group
6/15/2018Maxim GroupUpgradeHold ➝ BuyHigh
i
Rating by Jason McCarthy at Maxim Group
6/4/2018HC WainwrightSet Price TargetBuy$42.00N/A
i
Rating by Ram Selvaraju at HC Wainwright
5/9/2018Maxim GroupReiterated RatingHoldLow
i
Rating by Jason McCarthy at Maxim Group
4/16/2018Maxim GroupReiterated RatingHoldHigh
i
Rating by Jason McCarthy at Maxim Group
3/6/2018HC WainwrightReiterated RatingBuy$72.00High
i
Rating by R. Selvaraju at HC Wainwright
3/5/2018Maxim GroupReiterated RatingHoldHigh
i
Rating by Jason Kolbert at Maxim Group
1/24/2018Maxim GroupReiterated RatingHoldMedium
i
Rating by Jason Kolbert at Maxim Group
12/21/2017HC WainwrightInitiated CoverageBuy$72.00High
i
Rating by R. Selvaraju at HC Wainwright
11/10/2017Maxim GroupDowngradeBuy ➝ HoldN/A
i
Rating by Jason Kolbert at Maxim Group
10/18/2017Maxim GroupSet Price TargetBuy$288.00N/A
i
Rating by Jason Kolbert at Maxim Group
8/22/2017Maxim GroupSet Price TargetBuy$288.00Medium
i
Rating by Jason McCarthy at Maxim Group
8/16/2017Maxim GroupSet Price TargetBuy$288.00High
i
Rating by Jason McCarthy at Maxim Group
8/10/2017Maxim GroupSet Price TargetBuy$288.00Low
i
Rating by Jason McCarthy at Maxim Group
8/8/2017Cantor FitzgeraldReiterated RatingOverweightHigh
i
Rating by M. Goldstein at Cantor Fitzgerald
7/27/2017Maxim GroupSet Price TargetBuy$288.00High
i
Rating by Gabrielle Zhou at Maxim Group
7/6/2017Maxim GroupSet Price TargetBuy$288.00High
i
Rating by Jason Kolbert at Maxim Group
6/27/2017Maxim GroupSet Price TargetBuy$288.00Low
i
Rating by Jason McCarthy at Maxim Group
6/13/2017Maxim GroupReiterated RatingBuy$288.00Low
i
Rating by Jason McCarthy at Maxim Group
5/25/2017Maxim GroupSet Price TargetBuy$288.00High
i
Rating by Jason McCarthy at Maxim Group
5/11/2017Maxim GroupSet Price TargetBuy$288.00High
i
Rating by Jason McCarthy at Maxim Group
5/5/2017Maxim GroupReiterated RatingBuy$288.00Low
i
Rating by Jason McCarthy at Maxim Group
4/12/2017Maxim GroupUpgradeHold ➝ Buy$288.00Medium
i
Rating by Jason Kolbert at Maxim Group
3/18/2017Cantor FitzgeraldSet Price TargetBuy$576.00High
i
Rating by Bryan Brokmeier at Cantor Fitzgerald
3/16/2017Maxim GroupDowngradeBuy ➝ HoldHigh
i
Rating by Jason Kolbert at Maxim Group
3/16/2017Piper Jaffray CompaniesDowngradeNeutral ➝ UnderweightHigh
i
3/10/2017S&P Equity ResearchBoost Price Target$111.60 ➝ $129.60N/A
i
12/14/2016Cantor FitzgeraldSet Price TargetBuy$576.00N/A
i
Rating by Bryan Brokmeier at Cantor Fitzgerald
11/30/2016Cantor FitzgeraldReiterated RatingBuyN/A
i
11/10/2016Cantor FitzgeraldReiterated RatingBuy$576.00N/A
i
10/6/2016Maxim GroupReiterated RatingBuy$648.00N/A
i
Rating by Jason Kolbert at Maxim Group
8/8/2016Cantor FitzgeraldUpgradeHold ➝ Buy$360.00 ➝ $504.00N/A
i
Rating by Bryan Brokmeier at Cantor Fitzgerald
8/5/2016Piper Jaffray CompaniesSet Price TargetHold$360.00 ➝ $288.00N/A
i
Rating by William Quirk at Piper Jaffray Companies
8/5/2016Maxim GroupBoost Price TargetBuy$648.00 ➝ $864.00N/A
i
Rating by Jason Kolbert at Maxim Group
7/6/2016Maxim GroupInitiated CoverageBuy$864.00N/A
i
Rating by Jason Kolbert at Maxim Group
6/6/2016Maxim GroupReiterated RatingBuyN/A
i
Rating by Jason Kolbert at Maxim Group
5/12/2016Piper Jaffray CompaniesReiterated RatingHold$576.00 ➝ $360.00N/A
i
Rating by William Quirk at Piper Jaffray Companies
5/12/2016SVB LeerinkReiterated RatingHoldN/A
i
Rating by Dan Leonard at SVB Leerink LLC
5/11/2016Cantor FitzgeraldReiterated RatingHold$360.00N/A
i
Rating by Bryan Brokmeier at Cantor Fitzgerald
4/28/2016ArgusDowngradeBuy ➝ HoldN/A
i
4/26/2016SVB LeerinkDowngradeOutperform ➝ Sector PerformN/A
i
4/25/2016SVB LeerinkDowngradeOutperform ➝ Market PerformN/A
i
Rating by D. Leonard at SVB Leerink LLC
4/25/2016Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$378.72 ➝ $576.00N/A
i
4/25/2016Cantor FitzgeraldDowngradeBuy ➝ Hold$648.00 ➝ $360.00N/A
i
Rating by Bryan Brokmeier at Cantor Fitzgerald
3/29/2016Avondale PartnersReiterated RatingMarket Perform$432.00N/A
i
3/28/2016Cantor FitzgeraldReiterated RatingBuy$720.00N/A
i
Rating by Bryan Brokmeier at Cantor Fitzgerald
3/12/2016Maxim GroupReiterated RatingBuyN/A
i
Rating by Jason Kolbert at Maxim Group
3/12/2016Piper Jaffray CompaniesReiterated RatingOverweight$576.00N/A
i
3/11/2016Cantor FitzgeraldReiterated RatingBuy$720.00N/A
i
Rating by Bryan Brokmeier at Cantor Fitzgerald
3/11/2016Janney Montgomery ScottDowngradeBuy ➝ NeutralN/A
i
(Data available from 3/8/2016 forward)
Cardiff Oncology logo
Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.
Read More

Today's Range

Now: $9.15
$9.12
$9.90

50 Day Range

MA: $16.75
$1.19
$24.71

52 Week Range

Now: $9.15
$0.70
$3.46

Volume

705,417 shs

Average Volume

648,892 shs

Market Capitalization

$100.75 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.04

Frequently Asked Questions

What sell-side analysts currently cover shares of Cardiff Oncology?

The following sell-side analysts have issued reports on Cardiff Oncology in the last twelve months: Zacks Investment Research.
View the latest analyst ratings for TROV.

What is the current price target for Cardiff Oncology?

0 Wall Street analysts have set twelve-month price targets for Cardiff Oncology in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Cardiff Oncology in the next year.
View the latest price targets for TROV.

What is the current consensus analyst rating for Cardiff Oncology?

Cardiff Oncology currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for TROV.

What other companies compete with Cardiff Oncology?

How do I contact Cardiff Oncology's investor relations team?

Cardiff Oncology's physical mailing address is 11055 FLINTKOTE AVENUE, SAN DIEGO CA, 92121. The medical research company's listed phone number is (858) 952-7570 and its investor relations email address is [email protected] The official website for Cardiff Oncology is www.trovagene.com.